PharmaDossier
Manufacturing

In-House HPLC Mobile Phase: What Records Support Its Use-By Time?

Check which records support in-house HPLC mobile phase use through the final planned injection, including storage, reservoir conditions, and timing.

Ran Chen
Ran Chen
15 min read · Published · Source-cited

What the mobile phase label can establish

A quality control (QC) analyst preparing an overnight high-performance liquid chromatography (HPLC) sequence picks up an in-house mobile phase bottle with a current use-by date. The assessment linked from the approved procedure covers sealed storage. The planned sequence uses a vented solvent reservoir on the instrument bench through the next morning. The analyst needs to know whether the existing evidence covers that setup for the entire run.

Use the preparation record to identify the bottle, the approved procedure to find the assigned use period, and the supporting assessment to verify the conditions behind that period. Check the formulation, preparation, container and closure, storage, and reservoir use. Then check whether the assessment covers the planned sequence through the final use of that mobile phase.

FDA includes mobile phases among laboratory reagents under § 211.194. Its Current Good Manufacturing Practice (CGMP) Q&A recommends documenting the established period in the procedure, labeling in-house preparations with their use-by dates at preparation, and discarding them at expiry. WHO § 5.55 allows general labeling information, such as storage conditions, on the container or in associated records, including a laboratory information management system (LIMS). Section 5.58 lists in-house label details such as the preparer, preparation date, validity period, and component information or a traceable reference. Section 5.61 recommends lifecycle procedures and preparation records (FDA Records and Reports Q&A, question 5, WHO TRS 1052, Annex 4, §§ 5.55, 5.58 and 5.61).

WHO recommends preparing, storing, and using mobile phases in line with authorized specifications and procedures and a relevant pharmacopoeia recognized by the national regulator. The guidance calls for scientifically justified use periods and preparation and use records. Three records answer different questions about the same bottle (WHO TRS 1025, Annex 4, §§ 9.1–9.3).

  • Preparation record and bottle label. Identify the preparation, preparer, dates, component lots, and preparation steps as applicable. The label and record link the bottle to the assigned period.

  • Approved standard operating procedure (SOP) or analytical method. Sets authorized preparation and handling, the assigned use period, any separate in-use limit, and disposal instructions.

  • Supporting expiry assessment. Explains why the period is justified and identifies the formulations, vessels, environments, and durations it covers.

WHO distinguishes checking expiry before use from recording which reagent was used. Section 5.51 says the date check itself need not be documented under that guidance and recommends recording use with traceability to at least the lot and expiry. The worksheet below addresses coverage for the specific run (WHO TRS 1052, Annex 4, § 5.51).

What supports the assigned use period

For U.S. finished pharmaceuticals, 21 CFR Part 211 supplies the binding CGMP framework. Section 211.160(a) requires quality control unit review and approval of laboratory controls and changes, contemporaneous documentation, and recorded justification for deviations. Section 211.160(b) requires scientifically sound laboratory controls. Section 211.194(a)(2) requires verification of method suitability under actual conditions of use. Section 211.194(c) requires complete records of any testing and standardization of laboratory reference standards, reagents, and standard solutions (21 CFR §§ 211.160 and 211.194).

Part 211 sets general laboratory-control and records requirements. The approved procedure supplies the assigned period for the preparation. FDA’s nonbinding Q&A explains the agency’s expectations for three types of laboratory materials (FDA Records and Reports Q&A, question 5).

  1. Purchased reagents and solvents. Follow the supplier’s assigned date when one is provided. FDA expects a suitable assessment when the supplier provides no expiry date. WHO recognizes the supplier’s date before opening and calls for a documented justification when supplier data are absent or when opening, transfer, or further processing affects quality (WHO TRS 1052, Annex 4, § 5.69).

  2. In-house mobile phases and other nonquantitative solutions. FDA expects an assessment to establish the expiry and says a suitable literature review may be acceptable. In a quantitative assay, apply this distinction to the mobile phase itself and date the separately prepared samples and standards using the evidence applicable to those solutions.

  3. In-house quantitative sample, standard, and titration solutions. FDA calls for formal stability studies to determine expiry. For procedures covering all three types of solutions, keep the evidence traceable to the preparation it supports.

FDA’s July 2015 guidance for drug and biologic applications recommends specifying reagent characteristics, storage conditions, and validated or documented shelf life where applicable in the analytical procedure. A reviewer can use that specification to locate the evidence supporting the assigned period and see which conditions it covers (FDA Analytical Procedures and Methods Validation, § IV.D).

AuthorityWhat it contributes to the decisionSource sections
21 CFR Part 211Binding U.S. laboratory controls, change approval, documentation, and verification of method suitability under actual conditions.§§ 211.160 and 211.194
FDA CGMP Records and Reports Q&AExpiry evidence by solution type, procedure instructions, labeling, and disposal.Question 5
FDA Analytical Procedures guidanceReagent details in the procedure and the distinct roles of suitability and transfer testing.§§ IV.D, IV.H and VIII.B.2
WHO good chromatography practicesJustified use periods, preparation and use records, and chromatographic performance checks.TRS 1025 Annex 4, §§ 9, 11.10–11.13 and 12.1
WHO good practices for pharmaceutical QC laboratoriesLabeling, storage, expiry justification, and handling of nonconforming work.TRS 1052 Annex 4, §§ 5.47–5.73 and 6.92–6.95

When an assessment relies on literature, review the conditions in the underlying report. A study on a component solvent under its original closure may support that component’s handling without addressing the prepared mixture after transfer. Compare what was tested with the formulation, container, storage, use conditions, and interval your procedure claims. Where they differ, look for a documented scientific rationale or relevant supporting data before applying the cited period. A reference that establishes only sealed storage leaves the in-use question open.

Check how the assessment handles consecutive exposures. For example, one report may evaluate a preparation at the end of sealed storage and another may evaluate freshly prepared eluent in the reservoir. The two reports describe different starting conditions for reservoir use. To apply both periods to the same bottle, look for data or a documented scientific rationale that addresses reservoir use after the proposed storage interval. Record the study or assessment reference alongside the procedure revision so the basis for that conclusion can be recovered when the method, bottle, or use period changes.

Match the assessment to the bottle and planned run

Opening a bottle or transferring the liquid can change the conditions behind the assigned period. WHO § 5.69 identifies exposure after opening or transfer as a reason to justify dating when that exposure affects reagent quality. For this in-house preparation, compare storage separately from on-instrument use. Record the actual reservoir closure and room conditions so a reviewer can compare them with the assessment (WHO TRS 1052, Annex 4, §§ 5.66–5.69, WHO TRS 1025, Annex 4, §§ 9.1–9.2).

Use this worksheet to compare the assessment with the bottle history and planned sequence. Fill it in from controlled records and identify gaps in the last column. Use the worksheet alongside the site’s authorized procedure.

What to checkAssessment or procedureActual bottle and planned runCoverage or action
Preparation ID and preparerApplicable preparation procedure and recordPreparation ID ________ Preparer ________Record reference ________
Preparation time and componentsApplicable grades and component use criteria ________Date and time ________ Component lots or record ________Match or gap ________
Controlling recordsSOP or method revision ________ Assessment reference ________Revision on preparation and sequence records ________Match or gap ________
Formulation and preparationComposition and applicable preparation steps ________Actual formulation and preparation details ________Covered or gap ________
Container and closureStorage vessel, closure, and reservoir configuration ________Actual storage bottle and intended reservoir, with cap and tubing ________Covered or gap ________
Storage conditionsTemperature, light protection, and other specified conditions ________Storage history, including any excursions ________Covered or gap ________
In-use reservoir conditionsAssessed room conditions, venting, and other relevant exposure ________Planned temperature, venting, and other relevant conditions ________Covered or gap ________
Timing through final useUse-by and time origin ________ In-use limit and time origin if defined ________Labeled use-by ________ Opening or loading time ________ Planned last use ________Earliest applicable cutoff or gap ________
Pre-run decisionApplicable SOP disposition ________Analyst ________ Reviewer if required ________Decision and record reference ________

In this hypothetical, the analyst has a buffer–acetonitrile mobile phase stored in a closed bottle in a monitored cabinet. The label is current. The assessment supports that preparation and its storage but is silent about the planned vented reservoir. That gap also leaves the duration of the in-use exposure unsupported.

Field in the hypothetical exampleAssessment scopeActual bottle and planned runCoverage or action
Controlling recordsCurrent SOP and assessment MP-ASSESS-01 for closed storagePreparation record A, Day 0 at 14:00, with component lots recordedTraceable under the current SOP
Formulation and preparationSpecified buffer–acetonitrile mixture and preparation stepsComposition and preparation match the SOPCovered
Container and closure during storageClosed glass bottle with the specified screw capStored in the specified bottle until Day 1 at 18:00Covered until opening
Storage conditionsMonitored cabinet within the approved rangeStored within that rangeCovered
In-use reservoir conditionsClosed storage onlyVented reservoir with inlet tubing on the instrument benchGap. The assessment does not cover this setup.
Timing through final useClosed-storage date runs past Day 2Planned exposure from Day 1 at 18:00 until Day 2 at 06:00In-use coverage undetermined for this 12-hour interval.
Pre-run decisionProcedure requires a supported setup and use intervalSequence has yet to startHold. Use a supported preparation and setup or seek quality review.

The preparation record shows that closed storage matched the assessment up to 18:00. The proposed setup differs from the assessed conditions for the next 12 hours. The lab has no basis in that record to carry the closed-storage period forward. Making a fresh batch of the same mixture would address elapsed time since preparation. The proposed reservoir and exposure would still need to be supported.

In a second hypothetical, the approved assessment covers the storage bottle and the specified reservoir and cap. The procedure sets an overall limit from preparation and a separate reservoir limit from hookup. The final injection is planned for 06:00 on Day 2. Count any required closing standard when identifying the final injection.

Field in the hypothetical exampleAssessment scopeActual bottle and planned runCoverage
Preparation and storageSame formulation, procedure, closed bottle, and monitored cabinetPreparation record B matches, with no storage excursionCovered
Reservoir and environmentSpecified reservoir, vented delivery cap, and instrument-room rangeReservoir, cap, and room conditions match the assessmentCovered
Overall use-by timeAssigned cutoff is Day 2 at 10:00Final injection planned for Day 2 at 06:00Within overall limit
In-use limitWith Day 1 hookup at 18:00, cutoff is Day 2 at 07:00Final injection planned for Day 2 at 06:00Within in-use limit. A delay past 07:00 requires reassessment under the SOP.

Use the time origin defined in the procedure and the earliest applicable cutoff. In the second example, the in-use deadline governs even though the overall use-by time is later. Allow time for equilibration, the full sequence, and any required closing checks. If a queue delay or pause changes the planned finish, recheck coverage under the site procedure. Where the procedure sets one period for the full storage and use history, verify coverage against that documented period.

What transfer and system suitability results cover

Look at the system suitability results and the transfer protocol for the conditions and time points they actually represent. Each can contribute evidence when the underlying data address the assigned use period.

FDA describes system suitability testing (SST) as checking performance of the integrated analytical system at the time of use. WHO includes SST in the sample set and recommends meeting the method-defined criteria before sample injections and throughout analysis. It describes bracketing standards at defined intervals where appropriate. Resolution, peak symmetry, and repeatability are examples of criteria that may be relevant to the method (FDA Analytical Procedures and Methods Validation, § IV.H, WHO TRS 1025, Annex 4, §§ 11.10–11.13 and 12.1).

A passing opening SST shows that the integrated system met the criteria at the point tested. For an overnight run, the expiry assessment must support the planned time and reservoir conditions. For related sequence and sample questions, see our guides on evaluating sample validity after HPLC system suitability passes and investigating suspected carryover peaks in HPLC blanks.

FDA describes transfer studies as typically protocol-driven comparisons between originating and receiving labs. The protocol sets the performance parameters and criteria, and the studies generally use representative test articles. Applicability to the mobile-phase period depends on the eluent history and conditions that the protocol and results capture. For related receiving-lab decisions, see our guides on setting analytical method transfer acceptance criteria and verifying an unchanged compendial method at a receiving QC lab (FDA Analytical Procedures and Methods Validation, § VIII.B.2).

When reviewing transfer or suitability data offered as evidence for dating, look for three links between the study and the proposed use period.

  • Relevant eluent age and exposure history. Trace the study runs to the formulation and preparation time. Check the vessel and closure used for storage and on the instrument and find the conditions recorded for each.

  • Evidence for the claimed end of use. Identify the longest relevant interval represented in the data and how the assessment justifies the proposed interval. Check which time points or sequence checks represent the conditions at the end of that period.

  • Method-relevant performance criteria. Check the results against criteria relevant to the intended use. WHO lists examples such as selectivity, sensitivity, peak symmetry, and repeatability, and addresses limits for detected blank interference. The assessment should explain what the observed performance contributes to dating.

A transfer with freshly prepared eluent at each site can support interlaboratory comparison at that eluent age. To use it for overnight reservoir dating, locate records that link representative aged eluent to the proposed storage and in-use conditions. If those records are missing, leave the in-use period unresolved.

When the planned use falls outside the assessed conditions

If a worksheet row shows a gap, hold the planned setup before the first injection. Follow the site’s procedure to use a preparation and reservoir configuration covered through final use or refer the gap to the quality unit. Record the specific missing condition so the reviewer can decide what evidence or procedural action is needed. Under § 211.160(a), changes to laboratory controls require quality control unit review and approval, and deviations from written controls require a record and justification (21 CFR § 211.160(a)).

  • FDA recommends that the procedure direct the laboratory to label in-house solutions at preparation and discard them at expiry (FDA Records and Reports Q&A, question 5).

  • WHO § 5.71 recommends appropriate disposal after expiry or when a reagent is no longer needed. Section 5.70 describes prolongation with a documented scientific justification and appropriate relabeling, including possible special-purpose uses (WHO TRS 1052, Annex 4, §§ 5.70–5.71).

For U.S. CGMP work, follow the approved procedure consistent with FDA’s expiry recommendations. Apply WHO’s prolongation provision within the jurisdiction and quality system that govern the laboratory.

If someone discovers the gap after acquisition, preserve the sequence data and records linking it to the preparation. Record the vessel, closure, and use interval that can be reconstructed. Handle any retention of the physical bottle or assembly under the site’s investigation and chemical-handling procedures. Section 211.194(a)(4) requires complete test data, and § 211.194(c) covers records of reagent testing and standardization (21 CFR § 211.194(a)(4) and (c)).

Use the site’s nonconforming-work process to identify the affected sequence and assess the impact on results, including earlier results where relevant. WHO recommends retaining the record and actions, choosing containment according to risk, determining acceptability, and defining who can authorize resumption. It also addresses customer notification and recall where needed and corrective action when recurrence or quality-system conformity is a concern (WHO TRS 1052, Annex 4, §§ 6.92–6.95).

Sources

  1. Agency interpretation of 21 CFR Part 211 covering mobile phases as laboratory reagents, expiry assessments vs. formal stability studies for quantitative solutions, SOP documentation, preparation labeling, and disposal at expiration. U.S. Food and Drug Administration — Questions and Answers on Current Good Manufacturing Practice Requirements—Records and Reports, Question 5 (July 19, 2011).

  2. Binding U.S. regulations establishing scientifically sound laboratory controls, QC unit review and approval, contemporaneous documentation, recorded/justified deviations, method suitability verification under actual conditions, and reagent/standard records. U.S. Government Publishing Office — 21 CFR Part 211, §§211.160 and 211.194 (Current Good Manufacturing Practice for Finished Pharmaceuticals, April 2025).

  3. Nonbinding guidance covering reagent documentation including storage conditions and validated or documented shelf life (§IV.D), system suitability testing at the time of use (§IV.H), and analytical method transfer studies (§VIII.B.2). U.S. Food and Drug Administration — Analytical Procedures and Methods Validation for Drugs and Biologics, Guidance for Industry (July 2015).

  4. Guidance addressing preparation, storage, scientifically justifiable timelines, and preparation/use records for solvents, buffers, and mobile phases (§§9.1–9.4), system suitability and bracketing standards (§§11.10–11.13), and chromatographic performance criteria (§12.1). World Health Organization — WHO Good Chromatography Practices, WHO Technical Report Series No. 1025, Annex 4 (2020).

  5. Guidance covering reagent lifecycle, labeling, preparation records, storage, expiry policy, documented justification upon opening/transfer, WHO prolongation and relabelling provisions, disposal (§§5.51, 5.55, 5.58, 5.61, 5.66–5.73), and nonconforming work (§§6.92–6.95). World Health Organization — WHO Good Practices for Pharmaceutical Quality Control Laboratories, WHO Technical Report Series No. 1052, Annex 4 (2024).

Ran Chen
Contributing Editor
Ran Chen

Founder, PharmaDossier. Life-sciences operator covering market access, specialty pharma, biosimilars, and regulated healthcare growth.

Follow on LinkedIn →